vs
WORKIVA INC（WK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
WORKIVA INC的季度营收约是再鼎医药的1.9倍（$247.3M vs $127.1M），WORKIVA INC同比增速更快（19.9% vs 17.1%），WORKIVA INC自由现金流更多（$25.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 18.0%）
Workiva Inc.是一家全球知名的SaaS企业，主打云原生关联报告合规平台，支持关联数据调用与报告流程自动化，可广泛应用于财务、会计、风险及合规等多个业务场景，助力企业提升运营效率与合规管理水平。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
WK vs ZLAB — 直观对比
营收规模更大
WK
是对方的1.9倍
$127.1M
营收增速更快
WK
高出2.8%
17.1%
自由现金流更多
WK
多$52.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
18.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.3M | $127.1M |
| 净利润 | $19.0M | — |
| 毛利率 | 80.4% | 51.0% |
| 营业利润率 | 25.8% | -54.6% |
| 净利率 | 7.7% | — |
| 营收同比 | 19.9% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.33 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收WKZLAB
| Q1 26 | $247.3M | — | ||
| Q4 25 | $238.9M | $127.1M | ||
| Q3 25 | $224.2M | $115.4M | ||
| Q2 25 | $215.2M | $109.1M | ||
| Q1 25 | $206.3M | $105.7M | ||
| Q4 24 | $199.9M | $108.5M | ||
| Q3 24 | $185.6M | $101.8M | ||
| Q2 24 | $177.5M | $100.1M |
净利润WKZLAB
| Q1 26 | $19.0M | — | ||
| Q4 25 | $11.8M | — | ||
| Q3 25 | $2.8M | $-36.0M | ||
| Q2 25 | $-19.4M | $-40.7M | ||
| Q1 25 | $-21.4M | $-48.4M | ||
| Q4 24 | $-8.8M | — | ||
| Q3 24 | $-17.0M | $-41.7M | ||
| Q2 24 | $-17.5M | $-80.3M |
毛利率WKZLAB
| Q1 26 | 80.4% | — | ||
| Q4 25 | 80.7% | 51.0% | ||
| Q3 25 | 79.3% | 59.5% | ||
| Q2 25 | 77.0% | 60.6% | ||
| Q1 25 | 76.6% | 63.6% | ||
| Q4 24 | 77.1% | 61.5% | ||
| Q3 24 | 76.5% | 64.1% | ||
| Q2 24 | 76.8% | 64.9% |
营业利润率WKZLAB
| Q1 26 | 25.8% | — | ||
| Q4 25 | 3.3% | -54.6% | ||
| Q3 25 | -1.5% | -42.3% | ||
| Q2 25 | -10.3% | -50.3% | ||
| Q1 25 | -12.0% | -53.3% | ||
| Q4 24 | -6.7% | -62.6% | ||
| Q3 24 | -11.7% | -66.6% | ||
| Q2 24 | -13.0% | -76.0% |
净利率WKZLAB
| Q1 26 | 7.7% | — | ||
| Q4 25 | 4.9% | — | ||
| Q3 25 | 1.2% | -31.2% | ||
| Q2 25 | -9.0% | -37.3% | ||
| Q1 25 | -10.4% | -45.8% | ||
| Q4 24 | -4.4% | — | ||
| Q3 24 | -9.2% | -40.9% | ||
| Q2 24 | -9.9% | -80.2% |
每股收益（稀释后）WKZLAB
| Q1 26 | $0.33 | — | ||
| Q4 25 | $0.21 | $-0.05 | ||
| Q3 25 | $0.05 | $-0.03 | ||
| Q2 25 | $-0.35 | $-0.04 | ||
| Q1 25 | $-0.38 | $-0.04 | ||
| Q4 24 | $-0.15 | $-0.09 | ||
| Q3 24 | $-0.31 | $-0.04 | ||
| Q2 24 | $-0.32 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $334.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $715.5M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资WKZLAB
| Q1 26 | $334.3M | — | ||
| Q4 25 | $338.8M | $689.6M | ||
| Q3 25 | $315.9M | $717.2M | ||
| Q2 25 | $284.3M | $732.2M | ||
| Q1 25 | $242.0M | $757.3M | ||
| Q4 24 | $301.8M | $779.7M | ||
| Q3 24 | $248.2M | $616.1M | ||
| Q2 24 | $267.9M | $630.0M |
股东权益WKZLAB
| Q1 26 | — | — | ||
| Q4 25 | $-5.4M | $715.5M | ||
| Q3 25 | $-36.9M | $759.9M | ||
| Q2 25 | $-66.5M | $791.7M | ||
| Q1 25 | $-75.7M | $810.8M | ||
| Q4 24 | $-41.7M | $840.9M | ||
| Q3 24 | $-50.8M | $667.7M | ||
| Q2 24 | $-77.7M | $704.2M |
总资产WKZLAB
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.3B | $985.3M | ||
| Q2 24 | $1.2B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $25.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 10.4% | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $171.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流WKZLAB
| Q1 26 | — | — | ||
| Q4 25 | $51.0M | $-26.0M | ||
| Q3 25 | $46.2M | $-32.0M | ||
| Q2 25 | $50.3M | $-31.0M | ||
| Q1 25 | $-7.4M | $-61.7M | ||
| Q4 24 | $44.0M | $-55.8M | ||
| Q3 24 | $18.9M | $-26.8M | ||
| Q2 24 | $-14.0K | $-42.2M |
自由现金流WKZLAB
| Q1 26 | $25.7M | — | ||
| Q4 25 | $50.7M | $-26.7M | ||
| Q3 25 | $46.1M | $-35.0M | ||
| Q2 25 | $49.3M | $-33.9M | ||
| Q1 25 | $-8.1M | $-63.2M | ||
| Q4 24 | $43.2M | $-58.4M | ||
| Q3 24 | $18.7M | $-28.2M | ||
| Q2 24 | $-122.0K | $-42.9M |
自由现金流率WKZLAB
| Q1 26 | 10.4% | — | ||
| Q4 25 | 21.2% | -21.0% | ||
| Q3 25 | 20.5% | -30.4% | ||
| Q2 25 | 22.9% | -31.1% | ||
| Q1 25 | -3.9% | -59.9% | ||
| Q4 24 | 21.6% | -53.8% | ||
| Q3 24 | 10.1% | -27.7% | ||
| Q2 24 | -0.1% | -42.9% |
资本支出强度WKZLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% |
现金转化率WKZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.31× | — | ||
| Q3 25 | 16.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
WK
| Subscription and support | $225.4M | 91% |
| Other | $22.0M | 9% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
